Dow Falls Over 200 Points; Micron Earnings Top Views
U.S. stocks fell Thursday, with the Dow Jones dropping 200 points. Micron (MU) reported Q4 revenue of $54.23B, beating estimates. Nexalin (NXL) and Stablecoin (SDEV) shares surged, while Corteva (CTVA) and NewGenIvf (NIVF) shares declined. Oil and gold prices rose, while European and Asian markets closed mixed.
How this was made
The 30-second read
Why it matters
Multiple companies disclosed material events, with Micron's earnings beat being the most significant primary disclosure.
Market read
Earnings beat and several corporate actions drive mixed reactions across sectors, influencing short‑term trading opportunities.
What to watch
Potential supply‑chain constraints for semiconductors and regulatory scrutiny on biotech collaborations could affect future performance.
Background
The article is a market wrap covering U.S. index moves, earnings, corporate deals, and macro data on Oct 1 2026.
Ticker impact
Micron reported Q4 2026 revenue of $54.23B and adjusted EPS $33.42, beating estimates.
likely upward pressure as the market prices in the earnings beat
Large-cap beat with strong revenue, immediate market reaction expected.
Nexalin signed a 10‑year exclusive distribution deal covering seven Latin American markets, sending shares up 90%.
likely continued pressure higher on the news of the distribution agreement
Significant share jump reflects market optimism.
Stablecoin Development Corp shares surged 60% to $4.15 after unspecified boost.
potential short‑term upside if momentum persists
No concrete catalyst provided beyond price move.
Veea announced an agreement with TROLLEE Holdings for phased deployment of VeeaONE solutions across 1,000 stores, shares up 44%.
likely upward pressure as deployment rollout proceeds
Deal size and deployment scope support price appreciation.
Corteva completed the spin‑off of its advanced seed and genetics business Vylor, shares fell 84%.
likely continued pressure as investors adjust to the new structure
Sharp price drop reflects market reaction to the spin‑off.
NewGenIvf Group closed a $1.25 million public offering, shares down 38% to $0.10.
likely downward pressure as capital raise signals financing need
Small raise but significant price decline.
Foghorn Therapeutics and Lilly discontinued their SMARCA2 degrader collaboration, shares fell 33% to $2.38.
likely further downside as pipeline setback is priced in
Partnership loss is material for a biotech.
Market effects
Semiconductor earnings beat may lift related chip stocks; biotech partnership loss drags sector sentiment.
U.S. indices slipped modestly, reflecting mixed reactions across sectors.
Limited to U.S. markets; commodity price moves noted but not directly tied to corporate news.
Counterpoint
Despite Micron's beat, broader market weakness could cap upside; investors may focus on sector rotation.
Key entities
- companyMicron Technology
Semiconductor manufacturer reporting Q4 2026 earnings.
- companyNexalin Technology
Micro‑cap biotech announcing a distribution deal.
- companyCorteva
Agricultural firm completing a spin‑off.
